These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32001948)

  • 21. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
    Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
    Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of dose modifications on the safety and efficacy of dacomitinib for
    Corral J; Mok TS; Nakagawa K; Rosell R; Lee KH; Migliorino MR; Pluzanski A; Linke R; Devgan G; Tan W; Quinn S; Wang T; Wu YL
    Future Oncol; 2019 Aug; 15(24):2795-2805. PubMed ID: 31313942
    [No Abstract]   [Full Text] [Related]  

  • 23. Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer.
    Wang S; Li J
    Onco Targets Ther; 2019; 12():6535-6548. PubMed ID: 31496745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
    Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
    J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib.
    Liu J; Lin S; Huynh A; Tan W
    Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38258127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of common adverse events related to first-line dacomitinib use in
    Zhou Q; Wu YL; Corral J; Nakagawa K; Garon EB; Sbar EI; Wang T; Sandin R; Noonan K; Gernhardt D; Mok TS
    Future Oncol; 2019 May; 15(13):1481-1491. PubMed ID: 30839234
    [No Abstract]   [Full Text] [Related]  

  • 27. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer.
    Brzezniak C; Carter CA; Giaccone G
    Expert Opin Pharmacother; 2013 Feb; 14(2):247-53. PubMed ID: 23294134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
    Peters S; Zimmermann S; Adjei AA
    Cancer Treat Rev; 2014 Sep; 40(8):917-26. PubMed ID: 25027951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.
    Kobayashi Y; Fujino T; Nishino M; Koga T; Chiba M; Sesumi Y; Ohara S; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
    J Thorac Oncol; 2018 May; 13(5):727-731. PubMed ID: 29410323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
    Kim DW; Garon EB; Jatoi A; Keefe DM; Lacouture ME; Sonis S; Gernhardt D; Wang T; Giri N; Doherty JP; Nadanaciva S; O'Connell J; Sbar E; Cho BC
    Lung Cancer; 2017 Apr; 106():76-82. PubMed ID: 28285698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer.
    Van Sebille YZA; Gibson RJ; Wardill HR; Ball IA; Keefe DMK; Bowen JM
    Int J Cancer; 2018 Jan; 142(2):369-380. PubMed ID: 28921512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dacomitinib: First Global Approval.
    Shirley M
    Drugs; 2018 Dec; 78(18):1947-1953. PubMed ID: 30506139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension.
    Yu X; Zhao X; Zhang J; Li Y; Sheng P; Ma C; Zhang L; Hao X; Zheng X; Xing Y; Qiao H; Qu L; Zhu D
    Eur J Pharmacol; 2019 May; 850():97-108. PubMed ID: 30753867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of dacomitinib in patients with HER2-positive gastric cancer.
    Oh DY; Lee KW; Cho JY; Kang WK; Im SA; Kim JW; Bang YJ
    Gastric Cancer; 2016 Oct; 19(4):1095-1103. PubMed ID: 26581547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
    Park K; Cho BC; Kim DW; Ahn MJ; Lee SY; Gernhardt D; Taylor I; Campbell AK; Zhang H; Giri N; Letrent SP; O'Connell J; Heo DS
    J Thorac Oncol; 2014 Oct; 9(10):1523-31. PubMed ID: 25521398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.
    Cavalieri S; Perrone F; Miceli R; Ascierto PA; Locati LD; Bergamini C; Granata R; Alfieri S; Resteghini C; Galbiati D; Busico A; Paielli N; Patuzzo R; Maurichi A; Gallino G; Ruggeri R; Mariani L; Palla M; Licitra L; Bossi P
    Eur J Cancer; 2018 Jul; 97():7-15. PubMed ID: 29734047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.
    Lacouture ME; Keefe DM; Sonis S; Jatoi A; Gernhardt D; Wang T; Doherty JP; Giri N; Nadanaciva S; O'Connell J; Sbar E; Piperdi B; Garon EB
    Ann Oncol; 2016 Sep; 27(9):1712-8. PubMed ID: 27287210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.